Form 4: Cyclo Therapeutics Director Toig Receives Stock Grant in Lieu of Cash Compensation

Director Randall M. Toig of Cyclo Therapeutics, Inc. received 10,516 shares of common stock on August 16, 2024, as compensation for the second quarter of 2024, in lieu of cash.

Summary

• Randall M. Toig, a director of Cyclo Therapeutics, Inc., received 10,516 shares of common stock on August 16, 2024.
• This transaction represents compensation for the second quarter of 2024, which Toig elected to receive in stock instead of cash.
• The shares were granted under the issuer's non-employee director compensation policy.
• The number of shares was calculated based on a closing price of $1.26 per share on August 16, 2024.
• Following the transaction, Toig beneficially owns 125,759 shares of Cyclo Therapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction (stock grant in lieu of cash compensation) and doesn't indicate any significant positive or negative development for the company.

Positives

• The director's decision to take stock in lieu of cash may signal confidence in the company's future prospects.
• The grant aligns the director's interests with those of the shareholders.

Industry Context

Director compensation in the form of stock grants is a common practice in publicly traded companies to align the interests of directors with those of shareholders. This encourages long-term value creation.

Comparison to Industry Standards

• Stock grants to non-employee directors are a common practice across the pharmaceutical industry.
• The size of the grant is relatively small, suggesting it is a standard compensation package.
• Comparable companies such as BioMarin Pharmaceutical and Vertex Pharmaceuticals also utilize stock options and grants as part of their director compensation packages.

Stakeholder Impact

• The stock grant dilutes existing shareholders' equity slightly.
• It aligns the director's interests with shareholders, potentially encouraging decisions that benefit the company's long-term value.

Key Dates